Breast cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Breast cancer recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Restoring Immunotherapy Sensitivity in Advanced Triple Negative Breast Cancer Using Ceralasertib, Durvalumab, and Paclitaxel Albumin-Bound https://clinicaltrials.eu/trial/study-on-restoring-immunotherapy-sensitivity-in-advanced-triple-negative-breast-cancer-using-ceralasertib-durvalumab-and-paclitaxel-albumin-bound/ Wed, 29 Apr 2026 15:00:49 +0000 https://clinicaltrials.eu/trial/study-on-restoring-immunotherapy-sensitivity-in-advanced-triple-negative-breast-cancer-using-ceralasertib-durvalumab-and-paclitaxel-albumin-bound/ This clinical trial is focused on studying a type of breast cancer known as advanced triple-negative breast cancer (TNBC). This form of cancer does not have the three common receptors known to fuel most breast cancer growth: estrogen, progesterone, and the HER2 protein. The study aims to explore the effectiveness of a treatment plan that includes a medication called ceralasertib, followed by a combination of two other medications, durvalumab and paclitaxel albumin-bound. Ceralasertib is taken in tablet form, while durvalumab and paclitaxel albumin-bound are given through an infusion, which means they are administered directly into the bloodstream.

The purpose of this study is to evaluate how well this treatment plan works for patients whose cancer has returned after previous treatments. The study will involve a period where participants will first receive ceralasertib to prepare their bodies, followed by the combination of durvalumab and paclitaxel albumin-bound. This approach is being tested to see if it can help restore the body’s sensitivity to immunotherapy, a type of treatment that uses the body’s immune system to fight cancer.

Participants in the study will be monitored over a period of time to assess the progression of their cancer and any responses to the treatment. The study will also track the overall health and survival of participants, as well as any side effects they may experience. The goal is to determine if this treatment plan can effectively control the cancer and improve the quality of life for those affected by advanced triple-negative breast cancer.

]]> Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-for-patients-with-high-risk-her2-negative-breast-cancer-after-standard-treatment/ Wed, 29 Apr 2026 15:00:29 +0000 https://clinicaltrials.eu/trial/study-of-sacituzumab-govitecan-for-patients-with-high-risk-her2-negative-breast-cancer-after-standard-treatment/ This study focuses on patients with HER2-negative breast cancer who still have residual disease after receiving standard neoadjuvant chemotherapy and are at high risk of cancer returning. The main treatment being investigated is sacituzumab govitecan, which is a specialized medication that combines an antibody with an anti-cancer drug, designed to target specific cancer cells.

The study compares two treatment approaches: patients will receive either sacituzumab govitecan or a standard treatment chosen by their doctor from several options including carboplatin, cisplatin, or capecitabine. The purpose is to determine if sacituzumab govitecan is more effective at preventing the cancer from returning compared to standard treatments.

Treatment will continue for up to 24 months. The medications are given either through an intravenous infusion directly into the bloodstream or as tablets taken by mouth, depending on which treatment the patient receives. All patients must have completed their previous treatments, including surgery and radiation therapy, before starting the study medication.

]]> Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery https://clinicaltrials.eu/trial/study-on-palbociclib-with-endocrine-therapy-for-patients-with-hormone-receptor-positive-her2-negative-local-or-regional-recurrence-of-breast-cancer/ Wed, 29 Apr 2026 14:30:30 +0000 https://clinicaltrials.eu/trial/study-on-palbociclib-with-endocrine-therapy-for-patients-with-hormone-receptor-positive-her2-negative-local-or-regional-recurrence-of-breast-cancer/ This study focuses on patients with hormone receptor-positive, HER2-negative breast cancer who have experienced a return of cancer in the same area after previous treatment (known as isolated locoregional recurrence). The study will test whether adding the medication palbociclib (also known as IBRANCE) to standard hormone therapy works better than hormone therapy alone.

The main purpose is to determine if using palbociclib together with hormone therapy for 3 years can help prevent the cancer from returning compared to using only hormone therapy. Palbociclib belongs to a group of drugs called CDK4/6 inhibitors, which work by blocking certain proteins that help cancer cells grow.

During the study, patients will receive either palbociclib tablets or capsules (at doses of 75 mg, 100 mg, or 125 mg) along with their regular hormone therapy, or they will receive only hormone therapy. The treatment will continue for up to three years, and doctors will monitor how well the treatment works and check for any side effects.

]]> Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer https://clinicaltrials.eu/trial/study-of-paclitaxel-carboplatin-and-durvalumab-with-or-without-oleclumab-for-patients-with-untreated-advanced-triple-negative-breast-cancer/ Wed, 29 Apr 2026 14:28:42 +0000 https://clinicaltrials.eu/trial/study-of-paclitaxel-carboplatin-and-durvalumab-with-or-without-oleclumab-for-patients-with-untreated-advanced-triple-negative-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as triple-negative breast cancer (TNBC). This form of cancer is characterized by the absence of three common receptors known to fuel most breast cancer growths: estrogen, progesterone, and HER2. The study is specifically for patients who have not received prior treatment and whose cancer has either returned locally and cannot be surgically removed or has spread to other parts of the body.

The trial is testing a combination of medications to see how effective they are in treating this type of cancer. The medications being studied include Paclitaxel, Carboplatin, and Durvalumab (also known by its code name MEDI4736). Some patients will also receive an additional medication called Oleclumab (code name MEDI9447). These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to determine the safety and potential benefits of these medications when used together. The study is divided into two phases. In the first phase, the focus is on confirming the safety of the combination of these drugs. In the second phase, the study aims to evaluate the clinical benefits, such as how well the cancer responds to the treatment, by comparing patients who receive the combination with and without Oleclumab. Participants will receive regular infusions and be monitored over time to assess the effects of the treatment.

]]> Study of DS-3939a for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-ds-3939a-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location and are difficult to treat. The trial will test a new treatment called DS-3939a, which is given as a solution through an intravenous infusion, meaning it is delivered directly into the bloodstream through a vein. The purpose of the study is to evaluate the safety and tolerability of DS-3939a and to see how well it works in treating these advanced cancers.

The study is divided into two parts. In the first part, participants will receive DS-3939a to assess its safety and how well it is tolerated by the body. In the second part, the study will continue to evaluate safety and also measure the treatment’s effectiveness at a recommended dose. This will involve looking at how the cancer responds to the treatment, which is known as the objective response rate. Participants may have different types of advanced cancers, including those of the lung, breast, ovary, and pancreas, among others.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups, laboratory tests, and imaging studies to track the progress of the treatment. The study aims to gather important information that could lead to new treatment options for people with advanced solid tumors. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of DS-3939a.

]]> Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer https://clinicaltrials.eu/trial/study-comparing-oral-paclitaxel-dhp107-and-iv-paclitaxel-for-patients-with-recurrent-or-metastatic-her2-negative-breast-cancer/ Wed, 29 Apr 2026 14:22:57 +0000 https://clinicaltrials.eu/trial/study-comparing-oral-paclitaxel-dhp107-and-iv-paclitaxel-for-patients-with-recurrent-or-metastatic-her2-negative-breast-cancer/ This clinical trial is focused on studying a type of breast cancer known as HER2-negative breast cancer, which can either come back after treatment or spread to other parts of the body. The study is comparing two forms of a cancer treatment called paclitaxel. One form is taken by mouth as an oral solution known as DHP107, and the other is given through a vein as an intravenous infusion called TAXOL. The purpose of the study is to see how well the oral form of paclitaxel works compared to the intravenous form in treating this type of breast cancer.

Participants in the study will receive either the oral or intravenous form of paclitaxel. The study will monitor how long the cancer does not get worse, which is known as progression-free survival. Other aspects being observed include how well the cancer responds to the treatment, the overall survival of participants, and the time it takes for the treatment to stop working. The study will also look at the overall control of the disease and the quality of life of the participants.

This trial is designed to provide important information about the effectiveness and safety of oral paclitaxel compared to the intravenous form. It aims to help determine if the oral form can be a suitable first-line treatment option for patients with recurrent or metastatic HER2-negative breast cancer. The study is expected to continue until November 2025.

]]>